PharmaLogic work contributes to glaucoma therapeutics

The American Academy of Ophthalmology recently updated its Glaucoma Practice Pattern. In this document, also published in the AAO’s Journal Ophthalmology, the Committee, headed by Steven J. Gedde, M.D., glaucoma is defined as a chronic, progressive optic neuropathy.  The document then further describes the best practices for diagnosis, follow-up and therapy.  Dr. Novack’s work on the issues of treatment adherence (patients taking their medication as prescribed) and performance (challenges to patients to properly use eyedrops).  His work on novel therapeutics drugs and devices is also cited.

About Dr. Novack

Dr. Gary Novack is a board-certified clinical pharmacologist and President of PharmaLogic Development with more than 40 years of experience in ophthalmic drug development, clinical research, and FDA regulatory strategy.

He has consulted for over 100 pharmaceutical and medical device companies and authored more than 400 scientific publications.

Contact Dr. Novack
Contact Dr. Novack